Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial

Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial

The gut microbiota is increasingly considered a contributory factor in metabolic dysfunction-associated steatotic liver disease (MASLD). This double-blind RCT evaluated the effect of three consecutive fecal microbiota transplantations (FMT) on hepatic steatosis in MASLD. Twenty patients with MASLD w...

Full description

Saved in:
Bibliographic Details
Main Authors: Bas Groenewegen, Merel M. Ruissen, Emily Crossette, Rajita Menon, Amanda L. Prince, Jason M. Norman, Bart E. P. B. Ballieux, Hildo J. Lamb, Elisabeth M. Terveer, Josbert J. Keller, Maarten E. Tushuizen
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Gut Microbes
Subjects:
Fecal microbiota transplantation (FMT)
metabolic dysfunction-associated steatotic liver disease (MASLD)
NAFLD
MRI-PDFF
hepatic steatosis
glucose tolerance
Online Access:https://www.tandfonline.com/doi/10.1080/19490976.2025.2541035
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/19490976.2025.2541035

Similar Items